News
FDA Removes Partial Clinical Hold on VG-3927 for Microglial Dysfunction in Alzheimer Disease
January 6th 2025Results from Vigil Neuroscience’s ongoing phase 1 trial of VG-3927 in healthy volunteers supported the continued development of the therapy as a potential once-daily oral treatment for Alzheimer disease.
Optimizing Serum GFAP and NfL Timing Enhances Accuracy in Assessing NMOSD Activity, Study Finds
January 5th 2025Ultimately, the biomarkers' temporal patterns may help differentiate attacks from remission, with sGFAP being particularly useful in distinguishing genuine attacks from pseudoattacks.
Expanding the Clinical Care of Friedreich Ataxia Through Omaveloxlone and SKYCLARYS PASS Registry
January 4th 2025David Lynch, MD, PhD, a professor of neurology at the University of Pennsylvania Perelman School of Medicine, discussed the significance of a number of recently presented analyses highlighting omaveloxlone, the first approved therapy for Friedreich ataxia.
Evolving MS Diagnostics From Categorical Classifications to Biological Phenotyping: Fred Lublin, MD
January 3rd 2025The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about the shift in multiple sclerosis diagnostics from rigid classification systems to a dynamic, spectrum-based approach focused on biological phenotyping. [WATCH TIME: 5 minutes]
Neurology Unwrapped: 2024’s Most Intriguing Conversations
December 27th 2024Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2024, with insights from Daniel Ontaneda, MD, PhD; Ian Kremer; Andy Berkowski, MD, PhD; Sameea Husain-Wilson, DO; Jonathan Parker, MD, PhD; and Lawrence Robinson, MD. [LISTEN TIME: 25 minutes]
Advancing the Diagnostic Criteria for Multiple Sclerosis: A New Era of Early Detection and Precision
December 24th 2024With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.
Understanding the Critical and Emerging Role of Complement in Neurological Disorders
December 23rd 2024The complement system is critical in immune defense and tissue homeostasis, but its dysregulation can contribute to autoimmune neurological disorders and neurodegenerative diseases like Alzheimer, ALS, and multiple sclerosis.
